Background Background The pharmacological
The pharmacological treatment of depression in nursing women treatment of depression in nursing women requires information on the magnitude of requires information on the magnitude of medication exposure totheinfantthat may medication exposure to the infantthat may occur through breast milk. occur through breast milk.
Aims Aims To examine serum concentrations
To examine serum concentrations of antidepressants in infants exposed to of antidepressants in infants exposed to these medications through breast-feeding. these medications through breast-feeding.
Method Method Maternal and infant serum
Maternal and infant serum concentrations of sertraline, paroxetine concentrations of sertraline, paroxetine and fluvoxamine were determined with and fluvoxamine were determined with high-performance liquid chromatography high-performance liquid chromatography (limit of detection (limit of detection1 ng/ml).
1 ng/ml).
Results
Results No detectable medication was No detectable medication was present in any infant exposed to present in any infant exposed to paroxetine ( paroxetine (n n16) or fluvoxamine ( 16) or fluvoxamine (n n4). 4). Among infants exposed to sertraline Among infants exposed to sertraline ( (n n30), detectable medication was 30), detectable medication was present in 24% of serum samples. A present in 24% of serum samples. A significant negative correlation was found significant negative correlation was found between infant age and infant serum between infant age and infant serum concentration. Sertraline was significantly concentration. Sertraline was significantly more likely to be detectedin aninfantifthe more likely to be detectedin aninfantifthe mother's daily dose was100 mg or higher. mother's daily dose was100 mg or higher. No adverse sequelae occurred in any No adverse sequelae occurred in any infant. infant.
Conclusions Conclusions This study shows that
This study shows that paroxetine, fluvoxamine and sertraline paroxetine, fluvoxamine and sertraline produce minimal exposure to infants when produce minimal exposure to infants when taken by nursing mothers. taken by nursing mothers.
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When new mothers experience depression, When new mothers experience depression, they and their clinicians need to know if they and their clinicians need to know if antidepressant medications are safe to use antidepressant medications are safe to use while breast-feeding. Several recent reports while breast-feeding. Several recent reports have examined the extent of exposure that have examined the extent of exposure that occurs to nursing infants whose mothers occurs to nursing infants whose mothers take antidepressants (e.g. Altshuler take antidepressants (e.g. Altshuler et al et al, , 1995; Taddio 1995; Taddio et al et al, 1996; Mammen , 1996; Mammen et al et al, , 1997; Stowe 1997; Stowe et al et al, 1997; Yoshida , 1997; Yoshida et al et al, , 1997; Wisner 1997; Wisner et al et al, 1998; Begg , 1998; Begg et al et al, , 1999; Birnbaum 1999; Birnbaum et al et al, 1999; Kristensen , 1999; Kristensen et et al al, 1999; Ohman , 1999; Ohman et al et al, 1999; Stowe , 1999; Stowe et al et al, , 2000) . However, the research literature 2000). However, the research literature has consisted largely of single cases or small has consisted largely of single cases or small studies, and methodological differences studies, and methodological differences have limited the information that can be have limited the information that can be drawn from them (Yoshida drawn from them (Yoshida et al et al, 1999) . , 1999). To expand this literature, we present To expand this literature, we present measurements of maternal and infant measurements of maternal and infant serum concentrations in 50 nursing serum concentrations in 50 nursing mother±infant pairs in which the mothers mother±infant pairs in which the mothers took therapeutic doses of sertraline, took therapeutic doses of sertraline, paroxetine or fluvoxamine. paroxetine or fluvoxamine.
METHOD METHOD
Fifty nursing mother±infant pairs who pre-Fifty nursing mother±infant pairs who presented to UCLA's Pregnancy and Post-sented to UCLA's Pregnancy and Postpartum Mood Disorders Program were partum Mood Disorders Program were included in the study. The women were included in the study. The women were Caucasian ( Caucasian (n n46), Hispanic ( 46), Hispanic (n n3) and 3) and Asian ( Asian (n n1), in good physical health, 1), in good physical health, ranging in age from 24 to 41 years old ranging in age from 24 to 41 years old and on standard doses of antidepressant and on standard doses of antidepressant medication, taken once daily for treatment medication, taken once daily for treatment of major depression. Two women addition-of major depression. Two women additionally were on nortriptyline and another was ally were on nortriptyline and another was on alprazolam. None of the infants was on on alprazolam. None of the infants was on medications of any category. Seventeen medications of any category. Seventeen women were on antidepressants during women were on antidepressants during pregnancy as well as nursing. Written pregnancy as well as nursing. Written informed consent was obtained from each informed consent was obtained from each mother for collection of serum samples. mother for collection of serum samples.
Sample collection Sample collection
Maternal and infant serum samples were Maternal and infant serum samples were obtained at a minimum of 2 weeks obtained at a minimum of 2 weeks following a fixed dose of antidepressant. following a fixed dose of antidepressant. For women who took the antidepressant For women who took the antidepressant during pregnancy, maternal and infant during pregnancy, maternal and infant serum samples were obtained a minimum serum samples were obtained a minimum of 2 weeks following delivery. Serum of 2 weeks following delivery. Serum samples were obtained from a total of 50 samples were obtained from a total of 50 infants and 48 mothers. infants and 48 mothers.
Detection of antidepressant Detection of antidepressant concentrations in serum concentrations in serum
The detection of sertraline, desmethyl-The detection of sertraline, desmethylsertraline, paroxetine and fluvoxamine in sertraline, paroxetine and fluvoxamine in serum was accomplished via an isocratic serum was accomplished via an isocratic high-performance liquid chromatography high-performance liquid chromatography (HPLC) separation followed by ultraviolet (HPLC) separation followed by ultraviolet detection at 225 nm. The concentration of detection at 225 nm. The concentration of each drug (sertraline, desmethylsertraline, each drug (sertraline, desmethylsertraline, paroxetine or fluvoxamine) in the samples paroxetine or fluvoxamine) in the samples was calculated from its peak area ratios was calculated from its peak area ratios by using the slope and intercept of the by using the slope and intercept of the appropriate calibration curve. The assays appropriate calibration curve. The assays had a lower limit of sensitivity of 1 ng/ml, had a lower limit of sensitivity of 1 ng/ml, defined by a signal-to-noise ratio of 7 for defined by a signal-to-noise ratio of 7 for each drug. each drug.
Statistical analysis Statistical analysis
The LIFEREG Procedure using SAS soft-The LIFEREG Procedure using SAS software was used to perform a Tobit analysis ware was used to perform a Tobit analysis on the data. The Tobit model is a regression on the data. The Tobit model is a regression model for left-censored data, assuming a model for left-censored data, assuming a normal distributed error term. The model normal distributed error term. The model parameters are estimated by maximum parameters are estimated by maximum likelihood. A likelihood. A w w 2 2 test was used to explore test was used to explore whether nursing infants whose mothers whether nursing infants whose mothers took higher daily doses of sertraline took higher daily doses of sertraline (100 mg or more) were more likely to (100 mg or more) were more likely to have detectable serum concentrations of have detectable serum concentrations of medication, as compared with infants of medication, as compared with infants of women who took lower doses. women who took lower doses.
RESULTS RESULTS
Results of the serum assays for the mother± Results of the serum assays for the mother± infant pairs are shown in Table 1 . Infant infant pairs are shown in Table 1 . Infant ages ranged from 2 to 60 weeks and ages ranged from 2 to 60 weeks and weights ranged from 3 to 10 kg at the time weights ranged from 3 to 10 kg at the time of the serum assays. of the serum assays.
No detectable medication was present No detectable medication was present in any infant exposed to paroxetine or in any infant exposed to paroxetine or fluvoxamine. Detectable medication (parent fluvoxamine. Detectable medication (parent and/or metabolite) was present in 24% and/or metabolite) was present in 24% (8/33) of the serum samples obtained from (8/33) of the serum samples obtained from infants exposed to sertraline. Concentra-infants exposed to sertraline. Concentrations of sertraline and desmethylsertraline, tions of sertraline and desmethylsertraline, when present, were 2±8 and 2±12 ng/ml, when present, were 2±8 and 2±12 ng/ml, respectively. respectively.
Four mothers (nos 5, 16, 24 and 49) Four mothers (nos 5, 16, 24 and 49) titrated their dose of the antidepressant titrated their dose of the antidepressant 140 5 51 1 n / a n/a n/a n/a 48 48
Fluvoxamine Fluvoxamine  100  100  No  No  100  100  13  13 6.8 6.8 5 51 1 5 51 1 n / a n/a n/a n/a 49a 49a Fluvoxamine Fluvoxamine 100 100 No No 100 100 9 9 5 . 2 5.2 n/o n/o 5 51 1 n / a n/a n/a n/a 49b 49b Fluvoxamine Fluvoxamine 150 150 No No 100 100 12 12 5.9 5.9 n/o n/o 5 51 1 n / a n/a n/a n/a 50 50
Fluvoxamine Fluvoxamine 150 150 Yes Yes 100 100 6 6 6 . 0 6.0 n/o n/o 5 51 1 n / a n/a n/a n/a n/o, not obtained; n/a, not available. n/o, not obtained; n/a, not available.
upwards to help their mood and obtained upwards to help their mood and obtained repeat serum samples on themselves and repeat serum samples on themselves and their infants after being on the higher their infants after being on the higher medication dosage for at least 1 week. medication dosage for at least 1 week. P0.008, respectively) after con-0.008, respectively) after controlling for infant age, gestational exposure trolling for infant age, gestational exposure and breast-feeding exposure. This analysis and breast-feeding exposure. This analysis used all the available maternal and infant used all the available maternal and infant serum samples shown in Table 1 . serum samples shown in Table 1 .
A significant negative correlation was A significant negative correlation was found between infant age and infant serum found between infant age and infant serum concentration of desmethylsertraline after concentration of desmethylsertraline after controlling for maternal dosage, gestational controlling for maternal dosage, gestational exposure and breast-feeding exposure (para-exposure and breast-feeding exposure (parameter estimate meter estimate7 71.46, d.f.
1.46, d.f.1, 1, P P0.002). 0.002). Among women who breast-fed fully, the Among women who breast-fed fully, the likelihood of their infants having a detect-likelihood of their infants having a detectable level of medication (sertraline or des-able level of medication (sertraline or desmethylsertraline) was significantly higher methylsertraline) was significantly higher if their dose was 100 mg or more ( if their dose was 100 mg or more (w w 2 2 6.81, d.f. 6.81, d.f.1, 1, P P0.009). 0.009). Mothers were questioned about poten-Mothers were questioned about potential adverse sequelae to their infants and tial adverse sequelae to their infants and did not report any such findings. Specific did not report any such findings. Specific enquiries were made regarding gastro-enquiries were made regarding gastrointestinal symptoms (e.g. vomiting, watery intestinal symptoms (e.g. vomiting, watery stool), lethargy, changes in sleep patterns stool), lethargy, changes in sleep patterns and easy bruising. None of the women in and easy bruising. None of the women in the study was on other medications and the study was on other medications and the infants were in good health. the infants were in good health.
DISCUSSION DISCUSSION
This study found that serum concentrations This study found that serum concentrations of medication were undetectable in all in-of medication were undetectable in all infants exposed to paroxetine or fluvoxamine fants exposed to paroxetine or fluvoxamine and in the majority of infants exposed to and in the majority of infants exposed to sertraline while nursing. When medication sertraline while nursing. When medication was present in the sertraline-exposed in-was present in the sertraline-exposed infants, it was usually in the form of the fants, it was usually in the form of the metabolite desmethylsertraline. Maternal metabolite desmethylsertraline. Maternal serum concentrations of sertraline and serum concentrations of sertraline and desmethylsertraline correlated highly with desmethylsertraline correlated highly with infant serum concentrations of desmethyl-infant serum concentrations of desmethylsertraline. Maternal dosage of sertraline sertraline. Maternal dosage of sertraline also correlated highly with infant serum also correlated highly with infant serum concentrations of desmethylsertraline; concentrations of desmethylsertraline; doses of 100 mg or above were significantly doses of 100 mg or above were significantly more likely to produce detectable concen-more likely to produce detectable concentrations in the infant. A significant negative trations in the infant. A significant negative correlation emerged between infant age and correlation emerged between infant age and serum concentration of desmethyl-serum concentration of desmethylsertraline. sertraline.
This study's findings suggest that This study's findings suggest that paroxetine, fluvoxamine and sertraline are paroxetine, fluvoxamine and sertraline are reasonable choices for nursing women reasonable choices for nursing women requiring treatment for depression. In requiring treatment for depression. In comparison with fluoxetine, these medi-comparison with fluoxetine, these medications appear to produce less exposure to cations appear to produce less exposure to nursing infants and have not been linked nursing infants and have not been linked with the adverse events of neonatal irrit-with the adverse events of neonatal irritability, sleep disturbance and poor feeding ability, sleep disturbance and poor feeding that have been reported in association with that have been reported in association with fluoxetine exposure through breast-feeding fluoxetine exposure through breast-feeding (Lester (Lester et al et al, 1993; Brent & Wisner, 1998; , 1993; Brent & Wisner, 1998; Chambers Chambers et al et al, 1999; Kristensen , 1999; Kristensen et al et al, , 1999) . For infants that are healthy and 1999) . For infants that are healthy and full-term, these findings provide no reason full-term, these findings provide no reason to discourage nursing among women taking to discourage nursing among women taking paroxetine, fluvoxamine or sertraline at paroxetine, fluvoxamine or sertraline at standard therapeutic dosages. The use of standard therapeutic dosages. The use of additional medications that are commonly additional medications that are commonly taken in the post-partum period (e.g. anti-taken in the post-partum period (e.g. antihistamines, decongestants, pain medi-histamines, decongestants, pain medications) should be kept to a minimum cations) should be kept to a minimum until more is known about whether such until more is known about whether such combinations are safe for the nursing infant combinations are safe for the nursing infant (Mitchell, 1999) . (Mitchell, 1999) . Birnbaum, C. S., Cohen, L. S., Baily, J.W., Birnbaum, C. S., Cohen, L. S., Baily, J.W., et al et al (1999) 
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